PI3K inhibitors in FL
| All patients (patients with FL) . | Duvelisib (PI3Kγ,δ)13 . | Idelalisib (PI3Kδ)14 . | Copanlisib (PI3Kα,δ)15 . |
|---|---|---|---|
| 129 (83) . | 125 (72) . | 142 (104) . | |
| Median prior therapies (range) | 3 (1-10) | 4 (2-12)* | 3 (2-9)* |
| Median time since progression, mo (range) | 3.2 | NA | 8.3 (1-73)* |
| ORR, % | 42 | 57* | 59 |
| CR, % | 1 | 6 | 14 |
| PR, % | 41 | 50 | 44 |
| SD, % | 34.9 | 34 | |
| PFS, mo | 9.5 | 11* | 11.2 |
| Discontinued due to adverse events, % | 31* | 20* | 25* |
| Key grade ≥3 adverse events with frequency >10% | Neutropenia, diarrhea, anemia, thrombocytopenia | Neutropenia, diarrhea, ALT elevation | Hyperglycemia, hypertension, neutropenia, pneumonia |
| All patients (patients with FL) . | Duvelisib (PI3Kγ,δ)13 . | Idelalisib (PI3Kδ)14 . | Copanlisib (PI3Kα,δ)15 . |
|---|---|---|---|
| 129 (83) . | 125 (72) . | 142 (104) . | |
| Median prior therapies (range) | 3 (1-10) | 4 (2-12)* | 3 (2-9)* |
| Median time since progression, mo (range) | 3.2 | NA | 8.3 (1-73)* |
| ORR, % | 42 | 57* | 59 |
| CR, % | 1 | 6 | 14 |
| PR, % | 41 | 50 | 44 |
| SD, % | 34.9 | 34 | |
| PFS, mo | 9.5 | 11* | 11.2 |
| Discontinued due to adverse events, % | 31* | 20* | 25* |
| Key grade ≥3 adverse events with frequency >10% | Neutropenia, diarrhea, anemia, thrombocytopenia | Neutropenia, diarrhea, ALT elevation | Hyperglycemia, hypertension, neutropenia, pneumonia |
ALT, alanine aminotransferase.
Whole study population.